Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

Clicks: 351
ID: 271584
2014
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Vedolizumab was not more effective than placebo in inducing clinical remission at week 6 among patients with CD in whom previous treatment with TNF antagonists had failed. The therapeutic benefits of vedolizumab in these patients were detectable at week 10. ClinicalTrials.gov number: NCT01224171.
Reference Key
be2014gastroenterologyeffects Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Sands BE;Feagan BG;Rutgeerts P;Colombel JF;Sandborn WJ;Sy R;D'Haens G;Ben-Horin S;Xu J;Rosario M;Fox I;Parikh A;Milch C;Hanauer S;;
Journal gastroenterology
Year 2014
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.